Trial Profile
An Open-Label, Dose Escalating Study to Evaluate the Safety of Intravaginal Oxybutynin in Subjects With Urge Urinary Incontinence.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Nov 2008
Price :
$35
*
At a glance
- Drugs Oxybutynin (Primary)
- Indications Urge incontinence
- Focus Therapeutic Use
- Sponsors FemmePharma Global Healthcare
- 19 Nov 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 24 Sep 2008 New trial record.